Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029509 · ClinicalTrials.gov registry record · Phase 1
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01029509: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01029509 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01029509, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
Interventions
- DRUG OPB 31121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029509
The ClinicalTrials.gov registry entry for NCT01029509 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OPB 31121 is the first listed.
NCT01029509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01029509 about?
NCT01029509 is a clinical study titled "Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes". The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
What is the current status of trial NCT01029509?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01029509?
The interventions under investigation include: OPB 31121 (DRUG).
Who is sponsoring clinical trial NCT01029509?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.